Sharon Brangman
speaker
219 appearances
2 recordings
1 series
first heard Jan 2023
last heard Aug 2023
Sharon Brangman’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
Are they gonna need a touch up?
Do you stop after a certain amount of amyloid is removed and then monitor them and then maybe give them another dose periodically?
I think these are all
Well the other thing is the APOE value and I've talked to colleagues who say they're not gonna check for APOE.
Oh that's
I think ApoE is important to check for because if you're a homozygous, you have an increased risk of bleeding.
And even if you're heterozygous, meaning you just have one strand, there's an increased risk.
So I think that's an important
Absolutely.
gonna be part of what we find out.
And you know, many people, many geriatricians and colleagues are gonna be um participating in databases where we collect information about people who are on these drugs.
And that may be one of the questions that we find out an answer to that if somebody does get an area of side effect, what does that do to their cognition and function moving forward?
So we are
Sure.
clinical trial period in a way because we only have 18 months worth of data.
And and one question I'd like to ask Nate or or or Jason is what are you going to do if somebody is in their nineties?
Because you know the cutoff for these drugs were I think 85.
Oh so that's another thing that has to get followed uh with time because it does appear that it there is significant shrinkage of the brain, but you don't know if that's just a point in time and that maybe the brain recovers after the amyloid is removed.
So this is another point of interest that we're gonna have to collect data on.
I anticipate
Showing 21–40 of 219 · page 2 of 11
← Previous
Next →